Skip to main content

Oxford Biomedica Licenses RNAi Tech from Carnegie Institute, UMMS

NEW YORK (GenomeWeb News) - Gene therapy company Oxford Biomedica said today that it has licensed the rights for RNA interference technology from the University of Massachusetts Medical School and the Carnegie Institute of Washington. 
 
Under the agreement, Oxford Biomedica receives non-exclusive rights under the Carnegie and UMSS licensing programs for the RNAi technology and exclusive rights for the technology’s gene therapy applications using lentiviral vectors.
 
Oxford Biomedica’s therapeutic vaccine and gene-based therapy programs are focused on oncology and neurotherapy.
 
Oxford Biomedica will provide an upfront payment, annual maintenance fees, milestone payments, and royalties on sales, the company said.
 
Further financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.